[Nilotinib treatment for imatinib resistant or intolerant chronic myelogenous leukemia.].
Wang
Ai-Hua
AH
Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China.
Zhou
Li
L
You
Jian-Hua
JH
Wang
Li
L
Li
Jun-Min
JM
Hu
Jiong
J
Shen
Zhi-Xiang
ZX
D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl